Is obesity a disease?
It’s one of the most polarizing topics in modern medicine at the moment.
Let’s look at the facts.
According to the world health organization, Obesity is defined as excessive fat that presents a health risk, and most- if not all- organizations recognize it as a chronic, metabolic disease and not just a cosmetic concern1. The numbers bear them out. According to the world obesity federation, as of 2024, More than one billion people now live with obesity worldwide2. In the UAE, these statistics translates to around one in four adult males living with obesity and one out of three adult females living with obesity3. Obesity is related to over 200 comorbidities, such as hypertension, heart failure, liver disease and diabetes. It’s clear there is an obesity crisis, and governments are rushing to address it, not only from a public health perspective but from a cost perspective as well.
Patients living with obesity are desperate for effective solutions, which is why GLP1-RAs are so popular. However, many patients find it difficult to maintain long-term weight loss. Much of the focus so far has been on the short-term – achieving the greatest weight loss in the shortest amount of time.
Against this backdrop, the conversation around GLP1- RA medicines have intensified, particularly regarding the importance of responsible use. Recent discussions have highlighted concerns about unintended health risks when weight loss occurs without appropriate healthcare oversight. The broader lesson is clear: weight loss alone does not automatically equal better health. Sustainable outcomes depend on comprehensive medical supervision, balanced nutrition, and long-term behavioural change.
GLP1-RA medicines should be prescribed strictly according to approved medical criteria and indications. These treatments are indicated as an adjunct to a reduced-calorie diet and increased physical activity, not a replacement for them. This distinction is critical. GLP1-RAs work by activating receptors in the brain, reducing hunger and supporting decreased calorie intake. However, appetite regulation must be paired with intentional nutritional planning. Adequate protein intake, balanced micronutrients, and muscle-preserving exercise are essential to protect lean body mass and prevent deficiencies.
The path forward lies in balance: combining pharmacological innovation with diet and physical activity, preserving muscle health, and maintaining ongoing clinical oversight. When used responsibly, GLP1-RA therapies can help people not only lose weight, but also gain health, confidence, and longevity, lifting burdens off individuals, families, and healthcare systems alike, while actively contributing to the UAE’s journey toward improved national wellbeing. A growing number of health professionals in the UAE support this more holistic approach to treating obesity, as does Novo Nordisk.
We recognize that if we are going to make a difference in treating obesity, not just for the individual, but for their families and children, we have to have a more holistic approach than just medication. That’s why we created campaigns such as “You Are the New Champion” and “Champion A Lighter You,” to help patients engage in medically guided, sustainable weight management rooted in education and empowerment.
Weight loss isn’t a fast fix. It’s a journey. And at Novo Nordisk, we are proud to be with you on yours.
